KURA Quote, Financials, Valuation and Earnings

AIM ImmunoTech has a net margin of -357.19% compared to Kura Oncology, Inc.'s net margin of -10571.43%. Kura Oncology, Inc.'s return on equity of -61.97% beat AIM ImmunoTech's return on equity of -256.33%.

Kura Oncology, Inc. has a consensus price target of $33.00, signalling upside risk potential of 235.03%. On the other hand AIM ImmunoTech has an analysts' consensus of $4.50 which suggests that it could grow by 11066.25%. Given that AIM ImmunoTech has higher upside potential than Kura Oncology, Inc., analysts believe AIM ImmunoTech is more attractive than Kura Oncology, Inc..

Kura Oncology, Inc. has a beta of 0.212, which suggesting that the stock is 78.81% less volatile than S&P 500. In comparison AIM ImmunoTech has a beta of 0.760, suggesting its less volatile than the S&P 500 by 23.953%.

Kura Oncology, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AIM ImmunoTech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kura Oncology, Inc. pays -- of its earnings as a dividend. AIM ImmunoTech pays out -- of its earnings as a dividend.

Kura Oncology, Inc. quarterly revenues are $20.8M, which are larger than AIM ImmunoTech quarterly revenues of $35K. Kura Oncology, Inc.'s net income of -$74.1M is lower than AIM ImmunoTech's net income of -$3.7M. Notably, Kura Oncology, Inc.'s price-to-earnings ratio is -- while AIM ImmunoTech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kura Oncology, Inc. is 8.28x versus 13.27x for AIM ImmunoTech. Usually stocks with elevated PS ratios are considered overvalued.

Armata Pharmaceuticals, Inc. has a net margin of -357.19% compared to Kura Oncology, Inc.'s net margin of -2301.55%. Kura Oncology, Inc.'s return on equity of -61.97% beat Armata Pharmaceuticals, Inc.'s return on equity of --.

Kura Oncology, Inc. has a consensus price target of $33.00, signalling upside risk potential of 235.03%. On the other hand Armata Pharmaceuticals, Inc. has an analysts' consensus of $9.00 which suggests that it could grow by 66.67%. Given that Kura Oncology, Inc. has higher upside potential than Armata Pharmaceuticals, Inc., analysts believe Kura Oncology, Inc. is more attractive than Armata Pharmaceuticals, Inc..

Kura Oncology, Inc. has a beta of 0.212, which suggesting that the stock is 78.81% less volatile than S&P 500. In comparison Armata Pharmaceuticals, Inc. has a beta of 1.240, suggesting its more volatile than the S&P 500 by 23.97%.

Kura Oncology, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Armata Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kura Oncology, Inc. pays -- of its earnings as a dividend. Armata Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Kura Oncology, Inc. quarterly revenues are $20.8M, which are larger than Armata Pharmaceuticals, Inc. quarterly revenues of $1.2M. Kura Oncology, Inc.'s net income of -$74.1M is lower than Armata Pharmaceuticals, Inc.'s net income of -$26.7M. Notably, Kura Oncology, Inc.'s price-to-earnings ratio is -- while Armata Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kura Oncology, Inc. is 8.28x versus 44.79x for Armata Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Curis, Inc. has a net margin of -357.19% compared to Kura Oncology, Inc.'s net margin of -243.36%. Kura Oncology, Inc.'s return on equity of -61.97% beat Curis, Inc.'s return on equity of -461.34%.

Kura Oncology, Inc. has a consensus price target of $33.00, signalling upside risk potential of 235.03%. On the other hand Curis, Inc. has an analysts' consensus of $14.00 which suggests that it could grow by 1117.39%. Given that Curis, Inc. has higher upside potential than Kura Oncology, Inc., analysts believe Curis, Inc. is more attractive than Kura Oncology, Inc..

Kura Oncology, Inc. has a beta of 0.212, which suggesting that the stock is 78.81% less volatile than S&P 500. In comparison Curis, Inc. has a beta of 4.025, suggesting its more volatile than the S&P 500 by 302.512%.

Kura Oncology, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Curis, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kura Oncology, Inc. pays -- of its earnings as a dividend. Curis, Inc. pays out -- of its earnings as a dividend.

Kura Oncology, Inc. quarterly revenues are $20.8M, which are larger than Curis, Inc. quarterly revenues of $3.2M. Kura Oncology, Inc.'s net income of -$74.1M is lower than Curis, Inc.'s net income of -$7.7M. Notably, Kura Oncology, Inc.'s price-to-earnings ratio is -- while Curis, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kura Oncology, Inc. is 8.28x versus 1.10x for Curis, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Protalix Biotherapeutics, Inc. has a net margin of -357.19% compared to Kura Oncology, Inc.'s net margin of 13.19%. Kura Oncology, Inc.'s return on equity of -61.97% beat Protalix Biotherapeutics, Inc.'s return on equity of 12.06%.

Kura Oncology, Inc. has a consensus price target of $33.00, signalling upside risk potential of 235.03%. On the other hand Protalix Biotherapeutics, Inc. has an analysts' consensus of $11.00 which suggests that it could grow by 511.11%. Given that Protalix Biotherapeutics, Inc. has higher upside potential than Kura Oncology, Inc., analysts believe Protalix Biotherapeutics, Inc. is more attractive than Kura Oncology, Inc..

Kura Oncology, Inc. has a beta of 0.212, which suggesting that the stock is 78.81% less volatile than S&P 500. In comparison Protalix Biotherapeutics, Inc. has a beta of -0.248, suggesting its less volatile than the S&P 500 by 124.798%.

Kura Oncology, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix Biotherapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kura Oncology, Inc. pays -- of its earnings as a dividend. Protalix Biotherapeutics, Inc. pays out -- of its earnings as a dividend.

Kura Oncology, Inc. quarterly revenues are $20.8M, which are larger than Protalix Biotherapeutics, Inc. quarterly revenues of $17.9M. Kura Oncology, Inc.'s net income of -$74.1M is lower than Protalix Biotherapeutics, Inc.'s net income of $2.4M. Notably, Kura Oncology, Inc.'s price-to-earnings ratio is -- while Protalix Biotherapeutics, Inc.'s PE ratio is 25.90x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kura Oncology, Inc. is 8.28x versus 2.29x for Protalix Biotherapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.